Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology
Public ClinicalTrials.gov record NCT00784303. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology
Study identification
- NCT ID
- NCT00784303
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Eisai Inc.
- Industry
- Enrollment
- 117 participants
Conditions and interventions
Conditions
Interventions
- Lenvatinib (DTC Cohort) Drug
- Lenvatinib (MTC Cohort) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 5, 2008
- Primary completion
- Apr 10, 2011
- Completion
- Mar 28, 2019
- Last update posted
- Apr 21, 2020
2008 – 2019
United States locations
- U.S. sites
- 23
- U.S. states
- 15
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Little Rock | Arkansas | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Los Gatos | California | — | — |
| Not listed | Mission Viejo | California | — | — |
| Not listed | Santa Monica | California | — | — |
| Not listed | Torrance | California | — | — |
| Not listed | Aurora | Colorado | — | — |
| Not listed | Orlando | Florida | — | — |
| Not listed | Tampa | Florida | — | — |
| Not listed | Roswell | Georgia | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Baltimore | Maryland | — | — |
| Not listed | Bethesda | Maryland | — | — |
| Not listed | Boston | Massachusetts | — | — |
| Not listed | Minneapolis | Minnesota | — | — |
| Not listed | Columbia | Missouri | — | — |
| Not listed | Jefferson City | Missouri | — | — |
| Not listed | Lebanon | New Hampshire | — | — |
| Not listed | Montclair | New Jersey | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Long Beach | Washington | — | — |
| Not listed | Seattle | Washington | — | — |
| Not listed | Madison | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00784303, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 21, 2020 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00784303 live on ClinicalTrials.gov.